Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
NCT04036188
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Plaque Psoriasis
- Vitamin D3
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Wright State University
- Last updated on ClinicalTrials.gov
- February 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Ohio · 1
- Wright State Physicians · Fairborn, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.